The Chairman Hans Peter Bøhn has today, 19 September 2018, subscribed for
40,106 new shares in PCI Biotech Holding ASA (the "Company") at a subscription
price of NOK 30 per share by exercising all his 40,106 subscription rights
allocated in the Company's ongoing rights issue. After the transaction, Hans
Peter Bøhn will have a total shareholding in the Company of 123,662 shares.
The boad member Lars Viksmoen has today, 19 September 2018, subscribed for
1,920 new shares in PCI Biotech Holding ASA (the "Company") at a subscription
price of NOK 30 per share by exercising all his 1,920 subscription rights
allocated in the Company's ongoing rights issue through his wholly owned
company, Stocken Invest AS. In addition, Stocken Invest AS has bought 1,580
subscription rights at an average price of NOK 4.40 per subscription right and
subsequently exercised the 1,580 acquired subscription rights. After the
transactions, Stocken Invest AS will have a total shareholding in the Company of
7,500 shares. Stocken Invest AS has previously entered into a guarantee
agreement of NOK 1,000,000 in relation to the rights issue, and the exercise of
subscription rights will, in compliance with the guarantee agreement, reduce the
guarantee liability correspondingly.
The board member Christina Herder has today, 19 September 2018, subscribed for
1,645 new shares in PCI Biotech Holding ASA (the "Company") at a subscription
price of NOK 30 per share by exercising 1,645 of her allocated subscription
rights in the Company's ongoing rights issue. In addition, she has sold her
remaining 2,365 subscription rights at an average price of NOK 4.40 per
subscription right. After the transactions, Christina Herder will have a total
shareholding in the Company of 10,000 shares.
Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, NO-0379 Oslo.
Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 9400 5757.
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.